Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Mol Endocrinol ; 67(4): 173-188, 2021 09 09.
Article in English | MEDLINE | ID: mdl-34382943

ABSTRACT

Epidemiological studies inversely associate BMI with breast cancer risk in premenopausal women, but the pathophysiological linkage remains ill-defined. Despite the documented relevance of the 'local' environment to breast cancer progression and the well-accepted differences in transcriptome and metabolic properties of anatomically distinct fat depots, specific breast adipose contributions to the proliferative potential of non-diseased breast glandular compartment are not fully understood. To address early breast cancer causation in the context of obesity status, we compared the cellular and molecular phenotypes of breast adipose and matched breast glandular tissue from premenopausal non-obese (mean BMI = 27 kg/m2) and obese (mean BMI = 44 kg/m2) women. Breast adipose from obese women showed higher expression levels of adipogenic, pro-inflammatory, and estrogen synthetic genes than from non-obese women. Obese breast glandular tissue displayed lower proliferation and inflammatory status and higher expression of anti-proliferative/pro-senescence biomarkers TP53 and p21 than from non-obese women. Transcript levels for T-cell receptor and co-receptors CD3 and CD4 were higher in breast adipose of obese cohorts, coincident with elevated adipose interleukin 10 (IL10) and FOXP3 gene expression. In human breast epithelial cell lines MCF10A and HMEC, recombinant human IL10 reduced cell viability and CCND1 transcript levels, increased those of TP53 and p21, and promoted (MCF10A) apoptosis. Our findings suggest that breast adipose-associated IL10 may mediate paracrine interactions between non-diseased breast adipose and breast glandular compartments and highlight how breast adipose may program the local inflammatory milieu, partly by recruiting FOXP3+ T regulatory cells, to influence premenopausal breast cancer risk.


Subject(s)
Adipose Tissue/metabolism , Breast/metabolism , Epithelium/metabolism , Interleukin-10/metabolism , Phenotype , Premenopause/metabolism , Adipocytes/immunology , Adipocytes/metabolism , Adiposity , Adult , Biomarkers , Breast/pathology , Breast Neoplasms/etiology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Cytokines/genetics , Cytokines/metabolism , Female , Gene Expression , Gonadal Steroid Hormones/blood , Gonadal Steroid Hormones/metabolism , Humans , Immunohistochemistry , Inflammation Mediators/metabolism , Middle Aged , Models, Biological , Obesity/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathology , Telomere/genetics , Telomere/metabolism , Young Adult
2.
Plast Reconstr Surg Glob Open ; 8(7): e2869, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32802634

ABSTRACT

Dermal regeneration templates such as Integra are effective reconstructive biomaterials used in a variety of soft-tissue defects. Fully understanding the complications associated with their use is paramount to improve outcomes and maximize patient safety. In this study, our purpose is to perform a comprehensive literature review to assess the previously reported infectious complications linked to Integra-based wound closure. METHODS: We conducted a systematic review of the literature to identify previous articles indexed in PubMed and Ovid for Integra and its synonymous terms. We used these search terms: [Integra OR (dermal regenerative matrix) OR (dermal regeneration matrix) OR (dermal regenerative template) OR (dermal regeneration template) OR (dermal substitute) OR (skin substitute) OR (artificial skin)] AND infection. RESULTS: Of the 3508 articles for initial review, 69 reported rates of infection, of which 26 reported ≥1 infection within their cohort. Of these 26 articles, the patients (n = 602) underwent Integra-based reconstruction in 1254 sites and had reported infections in 212 of the sites (16.9%). Among these, we encountered a single report of a fatal case of toxic shock syndrome (TSS) related to the use of Integra in secondary burn reconstruction. CONCLUSIONS: While Integra offers many benefits, surgeons must be aware that infectious complications are not uncommon. As a result, a careful risk-benefit analysis of its use in reconstruction must be performed, and open discussion with the patient preoperatively regarding infection rate is of utmost importance.

3.
Hand (N Y) ; 10(2): 184-90, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26034428

ABSTRACT

BACKGROUND: Arterialized venous flow-through (AVFT) flaps are useful in reconstructing small soft tissue defects. Currently, no guidelines exist for the use of AVFT flaps for reconstructing soft tissue defects in the digits of the hand. We retrospectively reviewed our experience with AVFT flaps and developed a selection process for vascular anastomoses. METHODS: We reviewed the use of AVFT flaps in a series of ten consecutive patients requiring reconstruction of small soft tissue defects of the fingers. RESULTS: Between 2006 and 2012, ten consecutive digital reconstructions were performed using AVFT flaps. Flap sizes ranged from 5 to 13.5 cm(2). Initial congestion was seen in all flaps and resolved within 3-7 days. Leeches were utilized in two cases. All cases achieved good functional results. Three illustrative cases from our series of ten are presented, each demonstrating key decision-making factors in selecting recipient and flap vessels for anastomosis. CONCLUSIONS: AVFT flaps appear congested post-operatively, resolving in days to weeks, and resulting in healthy coverage of digital soft tissue defects with good functionality. We suggest a selection process for the use of AVFT flaps in digital soft tissue reconstruction, based on dorsal vs. volar and proximal vs. distal defect location, and the flap's inherent venous architecture.

4.
Int J Radiat Oncol Biol Phys ; 69(2 Suppl): S106-8, 2007.
Article in English | MEDLINE | ID: mdl-17848273

ABSTRACT

PURPOSE: Cisplatin resistance remains a barrier to organ-sparing and survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Targeted therapies to overcome cisplatin-resistant HNSCC are being developed. METHODS AND MATERIALS: Cisplatin-sensitive parental HNSCC cell lines and cisplatin-resistant progeny were studied. Pretreatment HNSCC biopsies were used to construct tissue microarrays which were stained for p53 and Bcl-xL. RESULTS: HNSCC cell lines selected for cisplatin resistance had wild-type p53 and high levels of Bcl-xL. Expression of wild-type p53 in cell lines with low Bcl-xL enhanced cisplatin sensitivity. Expression of both Bcl-xL and wild-type p53 caused tumor cells to become cisplatin resistant. Patients whose tumors expressed low levels of p53 and Bcl-xL enjoyed the best organ preservation and disease-free survival whereas patients whose tumors expressed low levels of p53 and high levels of Bcl-xL had the worst outcome. Novel agents that inhibit Bcl-xL or activate p53 function may target cisplatin-resistant HNSCC. CONCLUSION: Cisplatin resistance in HNSCC is mediated, at least in part, by high Bcl-xL and functional p53.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Drug Resistance, Neoplasm , Head and Neck Neoplasms/metabolism , Neoplasm Proteins/metabolism , Tumor Suppressor Protein p53/metabolism , bcl-X Protein/metabolism , Antineoplastic Agents/therapeutic use , Apoptosis/genetics , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/radiotherapy , Cell Line, Tumor , Cisplatin/therapeutic use , Drug Resistance, Neoplasm/genetics , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/radiotherapy , Humans , Neoplasm Proteins/antagonists & inhibitors , Tissue Array Analysis/methods , Tumor Suppressor Protein p53/antagonists & inhibitors , bcl-X Protein/antagonists & inhibitors
5.
Cancer Res ; 66(23): 11348-59, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17145881

ABSTRACT

The RAS/BRAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway is emerging as a key modulator of melanoma initiation and progression. However, a variety of clinical studies indicate that inhibiting the MAPK pathway is insufficient per se to effectively kill melanoma cells. Here, we report on a genetic and pharmacologic approach to identify survival factors responsible for the resistance of melanoma cells to MEK/ERK antagonists. In addition, we describe a new tumor cell-selective means to bypass this resistance in vitro and in vivo. By generating a panel of isogenic cell lines with specific defects in the apoptotic machinery, we found that the ability of melanoma cells to survive in the absence of functional MEK relies on an ERK-independent expression of the antiapoptotic factor Mcl-1 (and to a lesser extent, Bcl-x(L) and Bcl-2). Using computer-based modeling, we developed a novel Bcl-2 homology domain 3 (BH3) mimetic. This compound, named TW-37, is the first rationally designed small molecule with high affinity for Mcl-1, Bcl-x(L), and Bcl-2. Mechanistic analyses of the mode of action of TW-37 showed a synergistic tumor cell killing in the presence of MEK inhibitors. Importantly, TW-37 unveiled an unexpected role of the MAPK pathway in the control of reactive oxygen species (ROS). This function was critical to prevent the activation of proapoptotic functions of p53 in melanoma cells, but surprisingly, it was dispensable for normal melanocytes. Our results suggest that this MAPK-dependent ROS/p53 feedback loop is a point of vulnerability of melanoma cells that can be exploited for rational drug design.


Subject(s)
Benzamides/pharmacology , Melanoma/metabolism , Mitogen-Activated Protein Kinases/metabolism , Reactive Oxygen Species/metabolism , Sulfones/pharmacology , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis/drug effects , Benzamides/chemistry , Butadienes/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Drug Synergism , Humans , MAP Kinase Signaling System/drug effects , Melanoma/pathology , Melanoma/prevention & control , Mice , Mice, Nude , Microscopy, Fluorescence , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Molecular Structure , Nitriles/pharmacology , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/genetics , RNA Interference , Sulfones/chemistry , Xenograft Model Antitumor Assays , bcl-2 Homologous Antagonist-Killer Protein/genetics , bcl-2 Homologous Antagonist-Killer Protein/metabolism , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism
6.
Neoplasia ; 8(3): 163-72, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16611409

ABSTRACT

Resistance to chemotherapy is a common problem encountered in the treatment of head and neck squamous cell carcinoma (HNSCC). Chemoresistant HNSCC tumors frequently overexpress antiapoptotic proteins, such as Bcl-x(L). (-)-gossypol, the negative enantiomer of a cottonseed polyphenol, binds to Bcl-x(L) and was recently been shown to inhibit HNSCC proliferation in vitro. In this study, we assessed the in vivo efficacy of (-)-gossypol in an orthotopic xenograft model of HNSCC, using two human HNSCC cell lines with high Bcl-x(L) expression levels. Both produced tumors in a murine floor-of-mouth model that mimics human HNSCC, exhibiting growth and invasion into adjacent tissues. Mice were randomized into three groups: vehicle control and two daily intraperitoneal (-)-gossypol treatment groups (5 and 15 mg/kg). Tumors were measured twice weekly. In the control group, tumors grew progressively, whereas in (-)-gossypol treatment groups, tumor growth was significantly suppressed. The mitotic rate in tumors from (-)-gossypol-treated animals was significantly lower than that in controls, and an increase in the percentage of apoptotic cells was observed in treated tumors versus controls. Residual tumors remained growth-suppressed for 2 weeks after cessation of (-)-gossypol treatment. Our results demonstrate that (-)-gossypol can inhibit tumor growth in an orthotopic model of aggressive HNSCC.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Apoptosis/drug effects , Carcinoma, Squamous Cell/drug therapy , Gossypol/therapeutic use , Laryngeal Neoplasms/drug therapy , Mouth Neoplasms/drug therapy , Neoplasm Proteins/antagonists & inhibitors , bcl-X Protein/antagonists & inhibitors , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/pharmacology , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor/drug effects , Cell Line, Tumor/transplantation , Cells, Cultured/drug effects , Gossypol/administration & dosage , Gossypol/pharmacology , Humans , Injections, Intraperitoneal , Keratinocytes/drug effects , Laryngeal Neoplasms/pathology , Mice , Mice, Nude , Mitotic Index , Mouth Neoplasms/pathology , Random Allocation , Xenograft Model Antitumor Assays
7.
Clin Cancer Res ; 10(22): 7757-63, 2004 Nov 15.
Article in English | MEDLINE | ID: mdl-15570010

ABSTRACT

PURPOSE: Bcl-xL overexpression is common in head and neck squamous cell carcinomas (HNSCC) and correlates with resistance to chemotherapy. Thus, a nonpeptidic, cell-permeable small molecule that mimics the BH3 domain of proapoptotic proteins may inhibit Bcl-xL function and have therapeutic potential for HNSCC by overcoming drug-resistance. (-)-Gossypol, the levorotatory isomer of a natural product isolated from cottonseeds and roots, was recently discovered to bind to the BH3 binding groove of Bcl-xL and Bcl-2. EXPERIMENTAL DESIGN: We investigated the in vitro effects of (-)-gossypol on HNSCC cell lines as well as on fibroblast and keratinocyte cultures by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell survival assays and assessed the results with respect to Bcl-2 family protein expression. RESULTS: We observed dose-dependent growth inhibition of 10 HNSCC cell lines at biologically achievable doses (2.5-10 micromol/L). (-)-Gossypol doses required to inhibit the growth of human fibroblast cell lines by 50% were 2- to 10-fold higher than for HNSCC cell lines. To inhibit human oral keratinocyte growth by 50%, (-)-gossypol concentrations were 2-to 3-fold higher than for HNSCC cell lines. CONCLUSIONS: There is a direct correlation between Bcl-xL-to-Bcl-xS ratios and sensitivity to (-)-gossypol. This agent induced apoptosis in a much higher proportion of cells with wild-type p53. Importantly, cell lines resistant to cisplatin were very sensitive to (-)-gossypol. These results demonstrate that (-)-gossypol has potent antitumor activity in HNSCC in vitro. This agent may be developed as a novel therapeutic agent for HNSCC, either alone or in combination with existing chemotherapeutic agents.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Gossypol/chemistry , Gossypol/pharmacology , Head and Neck Neoplasms/drug therapy , Peptide Fragments/chemistry , Proto-Oncogene Proteins/chemistry , Apoptosis , Blotting, Western , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Proliferation , Cell Survival , Dimerization , Dose-Response Relationship, Drug , Drug Resistance , Fibroblasts/metabolism , Head and Neck Neoplasms/pathology , Humans , In Situ Nick-End Labeling , Inhibitory Concentration 50 , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/chemistry , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins c-bcl-2/pharmacology , Tetrazolium Salts/pharmacology , Thiazoles/pharmacology , Time Factors , Tumor Suppressor Protein p53/metabolism , bcl-X Protein
8.
J Trauma ; 55(1): 130-4, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12855892

ABSTRACT

BACKGROUND: Exercise treadmills have grown in popularity in the past few years. The addition of this type of equipment in the home offers opportunity for injury, particularly in children. METHODS: Patients were identified both prospectively and retrospectively by review of the trauma registry and medical records. Patient data, medical treatment, and hospital costs were obtained from medical records. Functional outcome was assessed by the modified Michigan Hand Outcomes Questionnaire. RESULTS: Nine patients were observed with 14 injuries. The average age was 3.4 years, with average clinical follow-up of 9.1 weeks. The primary injury was friction burn (eight of nine), with one patient sustaining a thumb distal tuft fracture. Two patients required operations and all patients had a good functional outcome (124.5 of 125 on the Michigan Hand Outcomes Questionnaire). CONCLUSION: Treadmill-associated injuries primarily involve hand injury in children. These injuries usually do not require surgical intervention and are preventable. Prevention modalities include additional manufacture safety features, warning labels, and parental education.


Subject(s)
Athletic Injuries/etiology , Hand Injuries/etiology , Accidents, Home/statistics & numerical data , Child , Child, Preschool , Female , Foot Injuries/etiology , Humans , Infant , Male , Medical Records , Prospective Studies , Recreation , Registries , Retrospective Studies , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...